Release of leukemia inhibitory factor in primate sepsis: Analysis of the role of TNF-α

Journal of Immunology

Volumn 156, Issue 11, 1996, Pages 4401-4407

  Jansen, Patty M ^a,e   De Jong, Irma W ^a   Hart, Margreet ^a   Kim, K Jin ^b   Aarden, Lucien A ^a   Hinshaw, Lerner B ^c   Taylor Jr , Fletcher B ^c   Hack, C Erik ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GENENTECH INC   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; LEUKEMIA INHIBITORY FACTOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CELL DAMAGE; CELL DIFFERENTIATION; DISEASE SEVERITY; ESCHERICHIA COLI; IMMUNOCOMPETENT CELL; NONHUMAN; PREDICTION; PRIMATE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SEPSIS;

EID: 0029931238     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457.
2. Hilton, D. J. 1992. LIF: lots of interesting functions. Trends Biochem. Sci. 17:72.
3. Mayer, P., K. Giessler, M. Ward, and D. Metcalf. 1993. Recombinant human leukemia inhibitory factor induces acute phase proteins and raises blood platelet counts in nonhuman primates. Blood 81:3226.
4. Gearing, D. P., M. R. Comeau, D. J. Friend, S. D. Gimpel, C. J. Thut, J. McGourty, K. K. Brasher, J. A. King, S. Gillis, B. Mosley, S. F. Ziegler, and D. Cosman. 1992. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255:1434.
5. Waring, P. M., L. J. Waring, T. Billington, and D. Metcalf. 1995. Leukemia inhibitory factor protects against experimental lethal Escherichia coli septic shock in mice. Proc. Natl. Acad. Sci. USA 92:1337.
6. Alexander, H. R., G. G. H. Wong, G. M. Doherty, D. J. Venzon, D. L. Fraker, and J. A. Norton. 1992. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin-1 and tumor necrosis factor. J. Exp. Med. 175:1139.
7. Block, M. I., M. Berg, M. J. McNamara, J. A. Norton, D. L. Fraker, and H. R. Alexander. 1993. Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J. Exp. Med. 178:1085.
8. Waring, P., K. Wycherley, D. Cary, N. Nicola, and D. Metcalf. 1992. Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids. J. Clin. Invest. 90:2031.
9. Villers, D., T. Dao, J.-M. Nguyen, E. Bironneau, A. Godard, M. Moreau, D. De Groote, F. Nicolas, J.-P. Soulillou, and I. Anegon. 1995. Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis. J. Infect. Dis. 171:232.
10. Waring, P. M., L. J. Waring, and D. Metcalf. 1994. Circulating leukemia inhibitory factor levels correlate with disease severity in meningococcemia. J. Infect. Dis. 170:1224.
11. Tomida, M., Y. Yamamoto-Yamaguchi, and M. Hozumi. 1984. Purification of a factor inducing proliferation of mouse myeloid leukemia M1 cells from conditioned medium of mouse fibroblast L929 cells. J. Biol. Chem. 259:10978.
12. Anegon, I., J.-F. Moreau, A. Godard, Y. Jacques, M.-A. Peyrat, M.-M. Hallet, G. Wong, and J.-P. Soulillou. 1990. Production of human interleukin for DA cells (HILDA)/leukemia inhibitory factor (LIF) by activated monocytes. Cell. Immunol. 130:50.
13. Lubbert, M., L. Mantovani, A. Lindemann, R. Mertelsmann, and F. Herrmann. 1991. Expression of leukemia inhibitory factor is regulated in human mesenchymal cells. Leukemia 5:361.
14. Metcalf, D. 1991. The leukemia inhibitory factor (LIF). Int. J. Cell Cloning 9:95.
15. Akira, S., T. Taga, and T. Kishimoto. 1993. Interleukin-6 in biology and medicine. Adv. Immunol. 54:1.
16. Creasy, A. A., P. Stevens, J. Kenney, A. J. Allison, K. Warren, R. Catlett, L. Hinshaw, and F. B. Taylor, Jr. 1991. Endotoxin and cytokine profile in plasma of baboons challenged with lethal or sublethal Escherichia coli. Circ. Shock 33:84.
17. Hinshaw, L. B., J. J. Coalson, B. A. Benjamin, L. T. Archer, B. K. Beller, O. R. Kling, E. M. Hasser, and R. W. Phillips. 1978. Escherichia coli shock in the baboon and the response to adrenocorticoidsteroid treatment. Surg. Gynecol. Obstet. 147:545.
18. 100 septic shock following steroid/antibiotic therapy. J. Surg. Res. 28:151.
19. 100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ. Shock 30:279.
20. Hinshaw, L. B., T. E. Emerson, Jr., F. B. Taylor, Jr., A. C. K. Chang, M. Duerr, G. T. Peer, D. J. Flournoy, G. L. White, S. D. Kosanke, C. K. Murray, R. Xu, R. B. Passey, and M. A. Fournel. 1992. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J. Trauma 33: 568.
21. Hinshaw, L. B., T. E. Emerson, Jr., A. C. Chang, M. Duerr, G. Peer, and M. Fournel. 1994. Study of septic shock in the non-human primate: relationship of pathophysiological response to therapy with anti-TNF antibody. Circ. Shock 44:221.
22. Kim, K. J., M. Alphonso, C. H. Schmelzer, and D. Lowe. 1992. Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA. J. Immunol. Methods 156:9.
23. Helle, M., L. Boeije, E. R. de Groot, A. de Vos, and L. A. Aarden. 1991. Sensitive ELISA for interleukin-6: detection of IL-6 in biological fluids: synovial fluids and sera. J. Immunol. Methods 38:47.
24. Jansen, P. M., J. van Damme, W. Put, I. W. de Jong, F. B. Taylor, Jr., and C. E. Hack. 1995. Monocyte chemotactic protein 1 (MCP-1) is released during lethal and sublethal bacteremia in baboons. J. Infect. Dis. 171:1640.
25. Fong, Y., K. J. Tracey, L. L. Moldawer, D. G. Hesse, K. B. Manogue, J. S. Kenney, A. T. Lee, G. C. Kuo, A. C. Allison, S. F. Lowry, and A. Cerami. 1989. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170:1627.
26. Van der Poll, T., M. Levi, S. J. H. van Deventer, H. ten Cate, B. L. Haagmans, B. J. Biemond, H. R. Büller, C. E. Hack, and J. W. ten Cate. 1994. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83:446.
27. Brown, M. A., D. Metcalf, and N. M. Gough. 1994. Leukaemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation. Cytokine 6:300.
28. Hack, C. E., E. R. de Groot, R. J. F. Felt-Bersma, J. H. Nuijens, R. J. M. Strack van Schijndel, A. J. M. Eerenberg-Belmer, L. G. Thijs, and L. A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704.
29. Alexander, H. R., G. M. Doherty, D. L. Fraker, M. I. Block, J. E. Swedenborg, and J. A. Norton. 1991. Human recombinant interleukin-1α protection against the lethality of endotoxin and experimental sepsis in mice. J. Surg. Res. 50:421.
30. Alexander, H. R., B. C. Sheppard, J. C. Jensen, H. N. Langstein, C. M. Buresh, D. Venzon, E. C. Walker, D. L. Fraker, M. C. Stovroff, and J. A. Norton. 1991. Treatment with recombinant human tumor necrosis factor-α protects rats against the lethality, hypotension, and hypothermia of Gram-negative sepsis. J. Clin. Invest. 88:34.
31. Görgen, I., T. Hartung, M. Leist, M. Niehörster, G. Tiegs, S. Uhlig, F. Weitzel, and A. Wendel. 1992, Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccaride-induced toxicity via suppression of systemic tumor necrosis factor-α. J. Immunol. 149:918.
32. Fey, G. H., and J. Gauldie. 1990. The acute phase response of the liver in inflammation. In Progress in Liver Disease, Vol. 9. H. Popper and F. Schaffner, eds. W. B. Saunders Company, Philadelphia, PA, p. 89.
33. Tilg, H., E. Trehu, M. B. Atkins, C. A. Dinarello, and J. W. Mier. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113.
34. Tilg, H., E. Vannier, G. Vachino, C. A. Dinarello, and J. W. Mier. 1993. Anti-inflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178:1629.
35. Heremans, H., C. Dillen, W. Put, J. van Damme, and A. Billiau. 1992. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur. J. Immunol. 22:2395.
36. Van der Poll, T., M. Levi, C. E. Hack, H. ten Cate, S. J. H. van Deventer, A. J. M. Eerenberg, E. R. de Groot, J. Jansen, H. Gallati, H. R. Büller, J. W. ten Cate, and L. A. Aarden. 1994. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 179:1253.
37. Barton, B. E., and J. V. Jackson. 1993. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. 51:1496.
38. Van der Meer, J. W. M., M. Helle, and L. A. Aarden. 1989. Comparison of the effects of recombinant interleukin-6 and recombinant interleukin-1 on nonspecific resistance to infection. Eur. J. Immunol. 19:413.
39. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Köhler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339.